SNDX

Syndax Pharmaceuticals, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-02-26

Figures on this page computed 2026-11-08 12:59 UTC

Last close

10.45USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-02-26

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
- computed
- 10-K for 2025, filed 2026-02-26
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-02
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-02
The filing itself
-165.6%Net margin
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
-187.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-K for 2025, filed 2026-02-26
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
- 10-K for 2025, filed 2026-02-26
- 10-Q for 2025, filed 2026-11-02
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Price is the furthest below its sector's middle: 0.15 against 0.38 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

5.02x

2.29x

2.68x

3.47x

0.68x

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Filed2025

Market data2026-11-04

Each against its own average

5 of 5 read

Except where said otherwise: 10-K for 2025, filed 2026-02-26

Sales5.02x
Its own average over 10 years, 34.4M.
Profit2.29x
Its own average over 10 years, -124.6M.
Free cash flow2.68x
Its own average over 9 years, -120.7M.
Debt3.47x
Its own average over 7 years, 99.1M.
Price0.68x
Its own average over 11 years, 15. Market data, 2026-11-04

Sales is furthest from its own average, at 5.02 times.

Sales is 5.02 times its own 10-year average; Profit is 2.29 times its own 10-year average; Free cash flow is 2.68 times its own 9-year average; Debt is 3.47 times its own 7-year average; Price is 0.68 times its own 11-year average.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-02-26

Sales against its own 10-year average5.02
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
The filing itself
Profit against its own 10-year average2.29
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
The filing itself
Free cash flow against its own 9-year average2.68
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
The filing itself
Debt against its own 7-year average3.47
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-076536
Reported in
USD
The filing itself
Price against its own 11-year average0.68Market data, 2026-11-04
Source
market
Taken on
2026-11-04
Reported in
USD